Strongbridge Biopharma plc (SBBP) financial statements (2020 and earlier)

Company profile

Business Address 900 NORTHBROOK DRIVE, SUITE 200
TREVOSE, PA 19053
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:7812258
Cash and cash equivalents5712258
Other undisclosed cash, cash equivalents, and short-term investments21  
Receivables222
Inventory, net of allowances, customer advances and progress billings241
Inventory241
Other undisclosed current assets141
Total current assets:8413261
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment000
Intangible assets, net (including goodwill)323742
Goodwill777
Intangible assets, net (excluding goodwill)253035
Other noncurrent assets101
Total noncurrent assets:343843
TOTAL ASSETS:118170104
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities211611
Accrued liabilities211611
Other undisclosed current liabilities311
Total current liabilities:241712
Noncurrent Liabilities
Long-term debt and lease obligation  38
Long-term debt, excluding current maturities  38
Liabilities, other than long-term debt1  
Other liabilities1  
Other undisclosed noncurrent liabilities204066
Total noncurrent liabilities:2140103
Total liabilities:4557116
Stockholders' equity
Stockholders' equity attributable to parent72113(12)
Common stock110
Additional paid in capital332323231
Accumulated other comprehensive income0  
Accumulated deficit(260)(211)(243)
Other undisclosed stockholders' equity000
Total stockholders' equity:72113(12)
TOTAL LIABILITIES AND EQUITY:118170104

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenues22187
Revenue, net7
Cost of revenue(4)(4)(1)
Cost of goods and services sold(4) (1)
Gross profit:18146
Operating expenses(85)(96)(79)
Operating loss:(67)(82)(74)
Nonoperating income (expense)19114(38)
Investment income, nonoperating 131 
Interest and debt expense (21)(4)
Income (loss) from continuing operations before equity method investments, income taxes:(48)11(115)
Other undisclosed income from continuing operations before income taxes 214
Income (loss) from continuing operations before income taxes:(48)32(112)
Income tax expense(2)(1)(2)
Net income (loss) available to common stockholders, basic:(49)32(113)
Other undisclosed net loss available to common stockholders, diluted(11)(16) 
Net income (loss) available to common stockholders, diluted:(61)16(113)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net income (loss):(49)32(113)
Comprehensive income (loss):(49)32(113)
Other undisclosed comprehensive income, net of tax, attributable to parent0  
Comprehensive income (loss), net of tax, attributable to parent:(49)32(113)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: